These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32738442)

  • 1. Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region.
    Stokes ES; Gilchrist ML; Calhoun DH
    Protein Expr Purif; 2020 Nov; 175():105710. PubMed ID: 32738442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
    Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
    Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of Fabry disease.
    Garman SC; Garboczi DN
    Mol Genet Metab; 2002; 77(1-2):3-11. PubMed ID: 12359124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
    Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
    Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
    Garman SC; Garboczi DN
    J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris.
    Chen Y; Jin M; Egborge T; Coppola G; Andre J; Calhoun DH
    Protein Expr Purif; 2000 Dec; 20(3):472-84. PubMed ID: 11087687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease.
    Ruderfer I; Shulman A; Kizhner T; Azulay Y; Nataf Y; Tekoah Y; Shaaltiel Y
    Bioconjug Chem; 2018 May; 29(5):1630-1639. PubMed ID: 29698600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.
    Ioannou YA; Zeidner KM; Grace ME; Desnick RJ
    Biochem J; 1998 Jun; 332 ( Pt 3)(Pt 3):789-97. PubMed ID: 9620884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.
    Andreotti G; Guarracino MR; Cammisa M; Correra A; Cubellis MV
    Orphanet J Rare Dis; 2010 Dec; 5():36. PubMed ID: 21138548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector.
    Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH
    Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cysteine variants on the structure, activity, and stability of recombinant human α-galactosidase A.
    Qiu H; Honey DM; Kingsbury JS; Park A; Boudanova E; Wei RR; Pan CQ; Edmunds T
    Protein Sci; 2015 Sep; 24(9):1401-11. PubMed ID: 26044846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
    Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
    Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
    Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease.
    Kase R; Bierfreund U; Klein A; Kolter T; Utsumi K; Itoha K; Sandhoff K; Sakuraba H
    Biochim Biophys Acta; 2000 Jun; 1501(2-3):227-35. PubMed ID: 10838196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
    Chiba Y; Sakuraba H; Kotani M; Kase R; Kobayashi K; Takeuchi M; Ogasawara S; Maruyama Y; Nakajima T; Takaoka Y; Jigami Y
    Glycobiology; 2002 Dec; 12(12):821-8. PubMed ID: 12499404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A.
    Saito S; Ohno K; Sakuraba H
    PLoS One; 2013; 8(12):e84267. PubMed ID: 24386359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of enzyme replacement therapy in Fabry disease.
    Barbey F; Hayoz D; Widmer U; Burnier M
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):277-86. PubMed ID: 15320778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.